The potential of chitosan-based haemostats for use in neurosurgical setting – Literature review. (December 2021)

• Record Type: Journal Article
• Authors: Sabab, Ahad; Vreugde, Sarah; Jukes, Alistair; Wormald, Peter-John
• Is Part Of: Journal of clinical neuroscience. Volume 94(2021)
• Page Start: 128
• Page End: 134
• Publication Date: 2021-12
• Subjects: GP IIb/IIA Glycoprotein IIb/IIa -- p-GlcNAc poly-N-acetyl glucosamine -- NO nitric oxide -- DDA degree of deacetylation -- MW molecular weight -- FDA Food and Drug Administration; Neurosurgery -- Chitosan -- Haemostasis -- Biotechnology; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2021.10.018
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Chitosan utilizes multiple mechanisms in order to induce hemostasis. Clinical research on the use of chitosan in neurosurgical use is lacking. In vivo research has found chitosan to be efficacious and safe for use in brain. Chitosan has similar efficacy and safety compared to other commercial hemostats. Clinical studies in various clinical (non-neurosurgical) contexts have found chitosan to be safe for human use. Abstract: Haemorrhage is a major nuance in neurosurgery since blood can distort the surgeon's field of view and increase the risk of post-operative complications. Currently a variety of commercially available haemostats have been approved for use in neurosurgery, but they have caveats to their use in the brain, including, localised tissue compression, neural toxicity, induce immune reaction or form thrombus within the vessel. Thus, there is a need for haemostats that are efficacious and safe for application on brain and spinal tissue. Chitosan is a naturally occurring bio-polymer that is found on the exoskeleton of arthropods and the cell wall of fungi. Chitosan has been shown to accelerate haemostasis through a myriad of physiological pathways. These findings have led to the development of multiple chitosan-based haemostats, for use in peripheral human tissue. Although, clinical data regarding the use of chitosan-based haemostats in the brain is lacking, a range on in vivo studies have proven chitosan to be efficacious and safe in managing neurosurgical bleeds. Similarly, literature comparing chitosan-based haemostats with commercial haemostats used commonly in neurosurgery, have all demonstrated chitosan to be the superior agent. Additionally, clinical trials of chitosan-based haemostat used in peripheral tissue have all demonstrated chitosan to be safe for human use. The marriage of these findings indicates that the safety and superior efficacy of chitosan-based haemostat, makes it a potentially suitable haemostat for use in neurosurgical setting. However, further research pertaining to the clinical use of chitosan-based haemostat within the central nervous system needs to be conducted.